Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Autolus Therapeutics says FDA has granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis. Enrollment in LUMINA, its pivotal Phase 2 study in refractory lupus nephritis, is ongoing.
Autolus Therapeutics says the FDA granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis.